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Abstract
Background: Despite tremendous progress in controlling the HIV epidemic in sub-Saharan Africa, HIV-related
mortality continues to increase among adolescents and young people living with HIV (AYPLHIV). Globally, sub-
Saharan Africa accounts for 85% of the AYPLHIV. Overall outcomes along the HIV care cascade are worse among
AYPLHIV as compared to all other age groups due to various challenges in accessing and adhering to antiretroviral
therapy (ART). New, innovative multicomponent packages of differentiated service delivery (DSD) models, are
required to address the specific needs of AYPLHIV. This study aims to evaluate the feasibility and effectiveness of a
multicomponent DSD model (PEBRA model) designed for AYPLHIV and coordinated by a peer-educator.
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Methods: PEBRA (Peer-Educator Based Refill of ART) is a cluster randomized, open-label, superiority trial conducted
at 20 health facilities in three districts of Lesotho, Southern Africa. The clusters (health facilities) are randomly
assigned to either the PEBRA model or standard of care in a 1:1 ratio, stratified by district. AYPLHIV aged 15–24
years old in care and on ART at one of the clusters are eligible. In the PEBRA model, a peer-educator coordinates
the antiretroviral therapy (ART) services - such as medication pick-up, SMS notifications and support options -
according to the preferences of the AYPLHIV. The peer-educator delivers this personalized model using a tablet-
based application called PEBRApp. The control clusters continue to offer standard of care: ART services coordinated
by the nurse. The primary endpoint is viral suppression at 12 months. Secondary endpoints include self-reported
adherence to ART, quality of life, satisfaction with care and engagement in care. The target sample size is 300
AYPLHIV. Statistical analyses are conducted and reported in line with CONSORT guidelines for cluster randomized
trials.
Discussion: The PEBRA trial will provide evidence on the feasibility and effectiveness of an inclusive, holistic and
preference-based DSD model for AYPLHIV that is coordinated by a peer-educator. Many countries in SSA have an
existing peer-educator program. If proven effective, the PEBRA model and PEBRApp have the potential to be scaled
up to similar settings.
Trial registration: Clinicaltrials.gov, NCT03969030. Registered on 31 May 2019. More information: www.pebra.info
Keywords: HIV, Adolescent, Lesotho, Africa, southern, Randomized controlled trial, Peer group, Antiretroviral
therapy, differentiated service delivery
Background
There is encouraging progress towards an AIDS-free
generation by 2030 on a global scale. However, this pro-
gress is challenged by persistent poor outcomes among
young people in sub-Saharan Africa (SSA). SSA accounts
for 85% of the adolescents and young people living with
HIV (AYPLHIV) worldwide. Almost one third of new
HIV infections occur among individuals aged 15–25
years, mostly in females [1, 2]. AYPLHIV is the only
population group for whom HIV-related mortality con-
tinues to increase and they are more likely to drop out
of HIV care, and have overall worse health outcomes
than all other age groups, especially in rural areas [3–7].
AYPLHIV face particular challenges in accessing and ad-
hering to ART. The distinct rapid physical, psychological
and emotional changes that occur during adolescence
impact on how AYPLHIV perceive their health, make
decisions, handle risks and interact with health and re-
lated services [8]. Thus, barriers in the adolescent HIV
care cascade are multifactorial [9–13]. Multicomponent
packages of differentiated service delivery (DSD) are a
promising approach to address these multiple barriers
[14, 15]. Unlike service delivery models that apply stan-
dardized care for all people living with HIV, the idea of
DSD models is to consider the specific needs of a group
of people, while facilitating service scale-up by reducing
the burden on health systems and increasing efficiency
[16, 17]. In 2018, Paediatric-Adolescent Treatment
Africa, in collaboration with other key stakeholders,
undertook a situational analysis of DSD for AYPLHIV in
South Africa [18]. They report a lack of published litera-
ture documenting adolescent-specific DSD models in
the Southern African region. Moreover, the analysis
shows that most adolescents are not accessing DSD
models even where they exist, an indicator that the
existing DSD models are not tailored according to
adolescent-specific preferences.
Many countries in SSA are expanding their peer-
educator (PE) program and the World Health
Organization (WHO) and International AIDS Society
highly recommend engagement of peers in service deliv-
ery [19, 20]. The question arises to which extent PEs can
be involved in coordinating DSD models and ART ser-
vices for their peers. Some evidence exists, including a
systematic review showing that PE involvement leads to
improved engagement in care, psychosocial well-being
and HIV knowledge, however, PE involvement is usually
limited to support group interventions in urban settings
with an unclear effect on biological outcomes [21–23].
One recent cluster-randomized clinical trial from rural
Zimbabwe demonstrated a positive impact of peer-led
services on psychosocial as well as virological outcomes
for AYPLHIV [24, 25].
Lesotho has the second-highest HIV prevalence in the
world with and adult prevalence of 25.6% and one of the
highest HIV incidences among adolescent girls and young
women [1, 26]. According to the recent household-based
national survey (LePHIA) overall viral suppression in
AYPLHIV is 50.9% among female and 46.1% among male
[27]. In close collaboration with different local stake-
holders, we designed a DSD model specifically for AYPL-
HIV, called the PEBRA model, built upon existing support
structures in Lesotho and delivered by a dedicated tablet
application. In the PEBRA model, PEs first assess the ART
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service preferences of their peers, and then differentiate
the services according to these preferences in a feasible
manner.
Methods/design
Setting
The PEBRA trial will be conducted in northern Lesotho,
in the districts of Leribe, Butha-Buthe and Mokhotlong.
All districts are characterized by mostly rural settings,
poor transport infrastructure and hard-to-reach villages
with a combined estimated population of ca. 550′000.
Butha-Buthe district comprises 12 public/missionary
health facilities, Leribe district 26, and Mokhotlong dis-
trict 10 that offer ART services. The HIV prevalence
among individuals 15–59 years old ranges from 17.8% in
Butha-Buthe, to 23.7% in Leribe and 26.1% in Mokhot-
long [27].
Design
PEBRA trial is a cluster randomized, open-label, super-
iority trial in rural Lesotho. The clusters (health facil-
ities) are randomized into two groups (intervention and
control) in a 1:1 allocation stratified by district. Cluster
randomization was applied to eliminate the risk of cross-
contamination between the study arms.
Eligibility and randomization
Eligible clusters are public or missionary nurse-led
health facilities (not hospitals) that offer ART services,
serve a rural population, are situated in an area with
stable cell phone signal and have a PE who passes the
study-specific training assessment. Randomization is
stratified by district due to differences in viral suppres-
sion rates across the districts. To obtain consent and to
maximize transparency and ownership of the health
facilities, randomization events involving all health facil-
ities and the District Health Management Team were
conducted in each district. At these events, health facility
representatives drew opaque, sealed, equally sized enve-
lopes containing the group allocation from a Mokorotlo
(traditional Lesotho hat) and disclosure took place only
once all facilities had drawn their envelope. To further
ensure allocation concealment and to minimize potential
selection bias, the sequence of drawing was randomly se-
lected in advance by an independent person drawing
from a second pile of opaque, sealed envelopes contain-
ing the names of the facility.
The PEs actively screen all young people at their facil-
ity for inclusion. Eligible individuals are attending care
at a participating facility, take ART, 15–24 years old, and
provide written informed consent.
Control clusters
Participants in the control clusters receive the standard
of care offered in Lesotho at nurse-led rural health facil-
ities. The ART visits and refills are clinic-based and
coordinated by the nurse. Some of the clinics have func-
tioning clinic or community support clubs as well as
SMS notifications to inform when VL results are
available.
Intervention clusters
The participants in the intervention clusters are offered
the PEBRA model. In the PEBRA model, the ART ser-
vices are coordinated by the PE as much as feasible and
depending on the participants’ preferences regarding
medication pick-up, SMS notifications and support
options. Details are outlined in Fig. 1. First, the PE
explains all options to the participant who then chooses
according to his/her preferences. Thereafter, the PE sys-
tematically assesses the feasibility of the option chosen
as not all options are available to everyone all the time,
e.g. no nearby Village Health Worker (VHW) available
who could dispense ART, or no community youth club
established in the participants’ community, or home-
delivery by the PE not being feasible. Finally, the com-
promise between preference and feasibility is delivered.
The preferences are assessed at enrolment and thereafter
follow a strict schedule: every month for participants
with unsuppressed VL (> 1000 copies/mL) and every 3
months for participants with suppressed VL. The PE
delivers the PEBRA model using a tablet-based applica-
tion, called PEBRApp (Fig. 2). The PEBRApp helps the
PE to assess the preferences, to deliver them in a feasible
manner, to keep track of the ART refill and next assess-
ment dates, and to ensure regular contact between the
PE and the participant. The PEBRApp is protected by a
password and does not entail confidential patient infor-
mation, i.e. names. The chosen SMS notifications are
sent automatically through an external platform, and
always include a call-back option to the PE’s number.
The PEBRA model and PEBRApp were designed in
collaboration with peer-educators, AYPLHIV, youth
advocates, clinical staff and application developers dur-
ing several workshops supported and coordinated by
two local non-profit organizations (SolidarMed &
Sentebale) as well as the Ministry of Health of Lesotho.
The model incorporates the existing support structures
at the health facilities. Sentebale is running a long-
standing PE program in collaboration with the Ministry
of Health. The study PEs are recruited from this existing
PE program. They are trained young people living in a
community of their respective health facility catchment
area. All PEs involved in PEBRA trial receive an
additional training on the PEBRApp and use of the tab-
let, referral and documentation system, obtaining
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Fig. 1 PEBRA intervention versus PEBRA control. Abbreviations: VHW (Village Health Worker), PE (Peer-Educator), CAC (Community Adherence
Club), TB (Treatment Buddy), ART (antiretroviral therapy), VL (viral load), FP (Family Planning), VMMC (Voluntary Medical Male Circumcision), GBV
(Gender-Based Violence), WORTH (Sentebale Social Asset Building Model). “Pitso” = Village gathering
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informed consent and other study-specific procedures.
Besides their usual close supervision by the health facil-
ity staff and Sentebale they are supervised by the study
staff with regular onsite monitoring visits.
Outcomes
The primary endpoint is viral suppression at 12 months,
defined as the proportion of participants in care with a
documented VL < 20 copies/mL 12months (range: 9–15
months) after enrolment out of all participants enrolled,
including participants who transferred out to any other
health facility with documented proof of a VL laboratory
report in the endpoint window. The secondary end-
points are defined in Table 1. Furthermore, qualitative
research to explore the acceptability of the PEBRA
model and a cost-effectiveness analysis to estimate the
impact of PEBRA model on health outcomes and costs
will be conducted.
Data collection and management
At enrolment, the PE administers a questionnaire inte-
grated in the PEBRApp. Questionnaire domains include
sociodemographic and socioeconomic data, medical his-
tory, HIV/AIDS knowledge, adherence, quality of life
and satisfaction of care. Follow-up data is collected using
PEBRApp according to the schedule outlined in Fig. 3.
Baseline VL is defined as the last VL within the previous
12months. If no VL within previous 12 months avail-
able, then the participant is sent to the nurse for routine
VL measurement at enrolment.
The PEBRApp is password-protected and all data is
regularly backed up into at a password-protected data-
base. Similarly, relevant data for the SMS intervention is
uploaded to a separate encrypted and password-
protected online database that offers the possibility to
send out SMS automatically and is connected to the dis-
trict laboratory database containing the VL results. SMS
are dispatched using the trusted third-party provider
Fig. 2 PEBRApp
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Twilio, certified with the privacy shield framework. Ac-
cess to all data collection tools and databases are strictly
limited and regulated through personal user profiles.
The PEBRA trial represents implementation research
without any experimental medication and only well-
established ART in Lesotho according to the National
guidelines. Thus, we do not expect serious adverse
effects (SAE) on patients’ health from this intervention.
However, for the purpose of this trial, we will capture
the following SAEs: a) life-threatening event, b)
hospitalization, c) persistent or significant disability or
incapacity, d) congenital anomaly / birth defect, e) death.
It is not planned to establish a data safety and monitor-
ing board.
Sample size and analysis
Based on cohort and program data from the study
districts we expect on average 15 AYPLHIV per health
facility with an overall viral suppression rate (< 20
copies/ml) of 70%. An overall target sample size of 300
AYPLHIV in 20 clusters would provide 90% power to
detect a 20% increase of viral suppression in the inter-
vention compared to the control group, assuming a type
1 error of 0.05. An intra-cluster correlation coefficient
(ICC) of 0.05 (design effect of 1.7) was estimated based
on similar studies [28, 29].
Analyses are performed following the CONSORT
guidelines for cluster-randomized trials and an
intention-to-treat principle including all participants as
Table 1 Secondary endpoints of PEBRA trial
Secondary
endpoints
Definition Time point following
enrolment
Remarks
Engagement
in care
Proportion of all participants engaged in care 6 months (range 5–8) and
12 months (range 9–15)
Definition of “in care”: at least one ART visit in the
defined window
I. Including participants who transferred out to any
other health facility with known outcome
(documented proof of follow-up visit or laboratory
test)
All cause
mortality
Proportion of all participants who died 6 months (range 5–8) and
12 months (range 9–15)
Verbal autopsy to capture cause of death whenever
possible. No death certificate or autopsy report
required.
Lost-to-
follow-up
(LTFU)
Proportion of all participants LTFU 6 months (range 5–8) and
12 months (range 9–15)
We define participants lost to follow-up if they or their
treatment buddies were more than 2 months late for
a scheduled consultation or medication pick-up and
no information was found about the participant
Transfer out
(TO)
Proportion of all participants who transferred out
to any other health facility (than the initially
attached one) with known outcome
6 months (range 5–8) and
12 months (range 9–15)
Definition of “known outcome”: Documented proof of
follow-up visit or laboratory test of the new health
facility
Viral
suppression
< 1000
copies/ml
Proportion of all participants with viral suppression
(< 1000 copies/mL)
12 months (range: 9–15) Some of the remote health facilities in the study
districts face regular challenges in sending the blood
to the government hospital. To ensure sufficient VL
measurements among study participants, these health
facilities will be equipped with dried-blood-spot (DBS)
as a backup for VL measurement. According to the
WHO the recommended threshold for treatment fail-
ure using DBS is 1000 copies/mL
Adherence Assessed by 3 different setting- and age-validated
ART self-reported adherence questions:
1. “When was the last time you missed any
medications?” [i) past week, ii) 1–2 weeks ago, iii)
3–4 weeks ago, iv) never]: Dichotomous outcome
missed doses vs. no missed doses in the past
month
2. “ART missed at two or more consecutive days
within last month?”: Dichotomous outcome
3. “How would you rate your adherence over the
last month” [i) very poor, ii) poor, iii) fair, iv) good,
v) very good, vi) excellent]: Dichotomous outcome
adherent vs non-adherent (anything less than
‘excellent’)
3 months (range 2.5–3.5),
6 months (range 5–8) and
12 months (range 9–15)
Quality of life Assessed by SF-12 (Likert-Scale) 6 months (range 5–8) and
12 months (range 9–15)
Satisfaction
of care
Assessed by a self-reported patient service satisfac-
tion questionnaire partly based on a setting-
validated quality of care questionnaire (Likert-Scale)
6 months (range 5–8) and
12 months (range 9–15)
Assessed by an external data collector, not the PE
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randomized per cluster randomization. Clusters are the
unit of randomization, but individuals are the unit of
analysis. The primary analysis uses random effects logis-
tic regression models including cluster as a random
effect and arm allocation as a fixed effect to assess the
difference between viral suppression rate in the interven-
tion versus control arm. The model will be further ad-
justed for the stratification factor, and relevant baseline
factors that may be randomly unbalanced between inter-
vention and control clusters. All results are presented
with odds ratios and their respective 95% confidence in-
tervals. Categorical variables will be described with abso-
lute and relative frequencies and continuous variables as
medians and interquartile ranges. In pre-specified sub-
group analyses, the effect of gender, age groups, educa-
tion, marital status, ART regimen and HIV/AIDS
knowledge on key study outcomes will be assessed by in-
cluding interaction terms in the model. If an interaction
term is found to be significant, effect estimates will be
summarized by subgroup. As the study is not powered
for these pre-planned subgroup analyses, these results
will be considered exploratory. Where substantial data
are missing in important covariates, multiple imputation
will be utilized and the results compared to models
ignoring missing data. A sensitivity analysis will be per-
formed to assess the effect of baseline viral load on the
primary endpoint, only including participants for whom
this data is available. All analyses are done using Stata
(version 14, Stata Corporation, Austin, Texas, USA),
using two-sided p-values and a significance level of 0.05.
Discussion
Effective and differentiated strategies are needed to
improve the HIV care cascade among adolescents and
young adults, especially in rural settings in SSA.
Although many countries in SSA have some sort of PE
program in place, there is lack of published high-quality
evidence for adolescent-specific DSD models involving
peers [20].
The Zvandiri DSD model in rural Zimbabwe intro-
duced community adolescent treatment supporters to
offer facility-based as well as community-based support
for AYPLHIV, including piloting ART delivery through
peers. In a small randomized clinical trial the model
improved self-reported adherence to ART, engagement
in care, and psychosocial well-being [24]. This effect
could no longer be observed at 2 years follow-up in a
subsequent larger cluster-randomized trial, however, a
40% reduction in virologic failure was documented
among participants in the model [25]. The questions
remain, though, to what extent DSD models can be indi-
vidualized and peers can be involved in clinical care. In
recent years there has been an increasing programmatic
shift towards DSD models, however they usually have
narrow inclusion criteria and limited options to choose
from. The PEBRA model tries to incorporate the existing
structures and support options provided by different
stakeholders, differentiates the DSD by personal prefer-
ences and puts the PE at the heart of the model.
This trial has several limitations. First, as in most oper-
ational research studies, we will have only limited con-
trol over what happens in our standard care clusters.
Second, due to the nature of this pragmatic implementa-
tion trial, it is not possible to blind participants or staff
to the intervention. Third, it was not feasible to perform
the randomization after recruitment of the participants.
That means, there is a possibility of recruitment bias. To
mitigate this risk, two different consent forms for
Fig. 3 PEBRA trial SPIRIT diagram
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control versus intervention arm concealing the exact
intervention of the other arm were used, thus the partic-
ipants were aware of being in a study, but not of being
in a trial.
The PEBRA trial will provide evidence on the feasibil-
ity and effectiveness of an inclusive and holistic DSD
model for AYPLHIV that is more preference-based and
coordinated by a PE. If proven to be effective, the
PEBRA model and PEBRApp have the potential to be
scaled up in similar settings.
Trial status
The trial was launched on November 4, 2019. The study
is ongoing, and we expect to reach the required mini-
mum target sample size within 5 months. The question-
naires, PEBRApp and the PEBRA model were pretested
in a pilot trial from August – October 2019. The pilot
trial assessed the acceptance of the PEBRA model and
its delivery by the PE, the technical functionalities of
PEBRApp and the questionnaires.
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